Heparin can induce heparin-induced thrombocytopenia (HIT). The combined effect of type of surgery (major vs minor) and heparin on this prothrombotic immune reaction to PF4/heparin was analyzed. In a randomized, double-blind, single center study, trauma patients receiving low-molecular-weight (LMWH) or unfractionated heparin (UFH) for thrombosis prophylaxis were assessed for PF4/heparin-antibody seroconversion, clinical HIT, and thrombosis according to type of surgery. PF4/heparin seroconversion (1.7% vs.6.6%; p=0.002) were less frequent, driven by differences in patients undergoing major surgery: incidence of HIT (LMWH 0.8% vs UFH 4.0%; p=0.180); seroconversion rates (4.0% vs 17.0%; p=0.001). After minor surgery no case of HIT occurred. The severity of trauma and the need for major surgery strongly influence the risk of forming an anti-PF4/heparin immune response, which is then increased by UFH. In major trauma certoparin may be safer than UFH as it induces HIT-antibody seroconversion -and the corresponding risk of HIT -less frequently. This study is registered at http://clinicaltrials.gov as NCT00196417.
Introduction
Low-molecular weight heparin and unfractionated heparin, the most widely used anticoagulants for thrombosis prophylaxis after surgery, 1 can induce a serious adverse drug reaction, heparin-induced thrombocytopenia (HIT). 2 HIT is an immune mediated prothrombotic syndrome in which patients develop platelet activating antibodies against platelet factor 4 (PF4)/heparin complexes 3 , resulting in a decrease of platelet counts, enhanced thrombin generation [4] [5] [6] and the paradox of an increased risk for thromboembolic complications despite heparin application.
The risk estimates for HIT in surgical patients are based on studies in patients undergoing elective major joint replacement surgery, [7] [8] [9] [10] which showed the risk for HIT being only approximately one-tenth as great when low-molecular-weight heparin is used for thrombosis prophylaxis as compared to unfractionated heparin. 11, 12 Whether the findings of these studies can be applied to other surgical patient populations is unresolved. It is especially unclear whether platelet count monitoring during the second week of heparin, for recognizing HIT, 12 should be recommended in the large group of patients with minor trauma, such as ankle fracture. This is of major clinical importance, as regular platelet count monitoring in this outpatient group is a burden for the patient and the health care system. We assessed the incidence of the immune response against PF4/heparin, and of clinical HIT, in a general trauma patient population with respect to type of heparin (unfractionated vs low-molecularweight heparin).
Furthermore, heparin is a classic biotherapeutic. Understanding the immune response to PF4/heparin might allow a better understanding of the mechanism of immune reactions towards other biotherapeutics. In this regard, the most important and surprising finding of our study is that the risk for HIT is largely influenced by a
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Patients and methods
This study was a double blind randomized controlled trial using a two arm parallel treatment design to demonstrate a lower incidence of HIT antibody seroconversion (superiority) in patients treated with low-molecular-weight heparin as compared to unfractionated heparin (ClinicalTrials.gov ID NCT00196417).
The study was approved by the Ernst-Moritz-Arndt-Universität IRB. Data analysis was performed by the authors, all of which had access to the primary clinical trial data.
Patients
From 01/2003-06/2005 consecutive patients admitted to the trauma surgery department, University Hospital Greifswald, Germany, were eligible for the study if they met all of the following criteria: age ≥ 18 years, expected in-patient period >4 days, and anticipated need for thrombosis prophylaxis >5 days. Exclusion criteria were: pregnancy, known drug-or alcohol abuse, need for therapeutic dose anticoagulation, intensive care treatment, and participation in another clinical study within the last 30 days. Patients who gave informed consent were immediately randomly allocated to one of two treatment strategies using sealed envelopes. The individuals assessing eligibility and assigning treatment allocation to the patient were not aware of the allocation schedule. No heparin was given before randomization.
Study medication
Patients received either unfractionated heparin 5,000 IU (B. Braun, Melsungen, Germany) t.i.d. s.c. or the low-molecular-weight heparin certoparin (Monoembolex, Novartis, Nürnberg, Germany) 3,000 anti-factor XaU o.d. s.c. and two placebo injections to ensure blinding of patients and study personnel. The first injection (given immediately after admission of the patient) always contained active study drug.
During subsequent days, the morning injection always contained low-molecularFor personal use only. on September 14, 2017. by guest www.bloodjournal.org From weight heparin in patients allocated to that study arm (secured by special coding of the morning injection in both groups).
Outcome measures
The primary outcome of this study was the difference in frequency of HIT-antibody seroconversion (defined subsequently) between the two treatment arms. Secondary outcomes were the occurrence of clinical HIT and occurrence of all-cause thrombosis (both non-HIT and HIT-associated). HIT was considered, if the patient had a 4T score of 4 or more points as agreed by two independent investigators and tested positive for anti-PF4/heparin IgG antibodies and showed platelet activating antibodies in the HIPA test. 13 Patients were observed until a study endpoint (HIT or new thrombosis) was reached. In case of an uneventful course, patients were followed from admission to discharge. After day 10 all patients received low-molecular-weight heparin. A follow up for thrombembolic events was performed 3 months after discharge.
In a second, prespecified analysis, patients were analyzed for seroconversion, clinical HIT and thromboses depending on severity of trauma and type of surgery.
Before study unblinding, patients were classified by the Abbreviated Injury Score All patients showing at least one positive result in the immunoassay or the HIPA test were assessed independently by two investigators using a validated clinical probability score for HIT, the 4Ts. 13 Disagreement was resolved by consensus.
Compression ultrasonography was performed as screening at discharge, or in case of clinical suspicion of deep vein thrombosis (DVT). All findings that were reported not to be within normal limits were adjudicated by an independent investigator blinded to treatment and outcome.
All patients received a questionnaire about clinical symptoms of thrombosis to be completed 3 months after discharge. In case this questionnaire was not returned a telephone interview was conducted.
Sample size
Sample size was calculated from estimated probabilities of seroconversion for low- The increase of platelet counts was compared by the chi-square test. The differences of thrombosis rates were compared by 2-sample t-test. All tests were two-sided and considered to be statistically significant below 0.05.
Role of the funding source
This study was supported by Novartis, Nürnberg, Germany. The sponsor had no role in study design, collection, analysis and interpretation of data, or in the writing of the manuscript.
Results

Patients
Of 696 patients enrolled, 614 were evaluable per protocol (low-molecular-weight heparin 298 [48.5%]; unfractionated heparin 316 [51.5%]). 53 patients received study medication <5d, and 29 withdrew consent during the study, primarily as they objected to three injections/day and additional daily blood sampling. Baseline characteristics were similar in both groups (table 1, figure 1 ).
Type of surgery and risk for the anti-PF4/heparin immune response and clinical HIT
The types of injury/procedure are given in table 2. Patients were grouped into major, minor, or no surgical procedures (table 2). The corresponding AIS were: AIS 1 (n=76; 62 minor; 14 no surgical procedure); AIS 2 (n=374; 120 major; 222 minor; 32 no Of the five patients that were adjudicated as having clinical HIT (table 3) , four received unfractionated heparin, and one received low-molecular-weight heparin (p=0.37). All had a positive HIPA and PF4/heparin IgG immunoassay, and associated DVT (4 proximal, 1 distal).
Logistic regression analysis of the immune response to PF4/heparin
The odds ratio (OR) for seroconversion (functional test and/or immunoassay) after major surgery vs minor surgery was 11.57 (95%CI 3.41-39.29; p<0.001); controlled for confounders (age, gender, type of heparin, length of heparin application) by logistic regression analysis, it was 7.98 (95%CI 2.06-31.00; p=0.003). The OR for a positive HIPA was 9.50 (95%CI 2.11-42.99; p=0.003); controlled for the above mentioned confounders, it was 7.30 (95%CI 1.37-38.94; p=0.020).
Risk for thrombosis related to type of surgery, type of heparin, and immune response to PF4/heparin
All thromboses: In the entire study population 17 patients had symptomatic DVT (11 proximal (1.8%; 95%CI 2.4-4.6%) and 6 distal (0.98%; 95%CI 0.2-1.8%), two patients had pulmonary embolism (0.3%; 95% CI 0.0-0.7%). In addition seven proximal DVT (1.1%; 95%CI 0.3-1.9%) and 18 distal DVT (2.9%; 95%CI 1.5-4.3%) were found by screening at discharge. In proximal DVT/PE following major surgical procedures (n=19) there was no difference in seroconversion rates depending on type of heparin (UFH vs. LMWH 3 [37.5% 95%CI: 4-71%] vs. 1 [9.1% 95%CI: 0-26.1%] p=0.134) but this might also be an effect of small numbers.
Two patients died during the in-hospital period: an 86 year old female patient died of pulmonary embolism (diagnosed clinically, no autopsy) at day 8 of unfractionated heparin prophylaxis following a fractured femur. There was no platelet count decrease suggestive of HIT. No blood sample for antibody testing was available. A 55 year old female patient died of pulmonary embolism (proven at autopsy) at day 14 after 7 days low-molecular-weight heparin prophylaxis following a fractured humerus.
There was no platelet count decrease, and HIT antibody tests at day 10 were negative. In patients undergoing minor surgical procedures there was a trend for an increased risk for DVT with PF4/heparin antibody seroconversion (HIPA and/or ELISA vs no antibodies, p=0.07).
Type of heparin:
The type of heparin (low-molecular-weight heparin/unfractionated heparin) did not correlate with the combined risk for proximal DVT and pulmonary embolism (p=0.56); the risk for developing an asymptomatic distal DVT (p=0.88); or the risk for any thrombotic event (p=0.91).
Platelet count profiles after major and minor surgical procedures
Platelet count profiles are shown in figure 3 . The platelet count decrease was greater after major surgery vs minor surgery: nadir (mean ± SD), day 3 (193,000 ± 65,100/mm 3 vs. 210,500 + 56,100/mm 3 ; p<0.001) with a higher reactive platelet count increase compared with the postoperative platelet count nadir (p<0.001): >50% (48.3% vs 15.6%); >30-49% (18.4% vs 14.3%); <30% (33.3% vs 72.6%) (Fig 3a) .
The 5 HIT patients developed their symptoms between day 5-10 ( Fig 3b) . The platelet count decrease in these patients was moderate only. This might have been the effect of close monitoring of patients within this prospective study.
For
months follow-up
In 599 patients (97.6%) follow-up information was obtained after 3 months. Of those, 26 (4.3%) had tested positive for PF4/heparin antibodies at discharge. The events after discharge, DVT (n=3), death (n=3, one pulmonary embolism suspected clinically), stroke (n=2), were not related to low-molecular-weight heparin/unfractionated heparin (p=0.73) or HIT antibody status at discharge (1/26 vs.
7/573, p=0.30).
Discussion
The most interesting finding of our study was that patients after major surgical procedures have a much higher risk for developing the immune response to PF4/heparin than patients undergoing minor surgical procedures irrespective of heparin type received. Thus a non-drug factor, namely the severity of trauma determining the need for major or minor surgery, is a marker for the immune response leading to the adverse drug reaction, HIT. The patients undergoing major and minor surgery differed in some of their characteristics, e.g. age and gender. We therefore controlled for potential confounders (age, gender, type of heparin, length of heparin application) by logistic regression analysis and still those patients undergoing major surgery had a much higher risk to develop the immune response against PF4/heparin (OR 7.98; 95%CI 2.06-31.00; p=0.003). However, we cannot differentiate whether this is a direct effect of trauma and inflammation or a more indirectly related association.
If one considers a more direct correlation between major surgery and the immune response against PF4/heparin possible, an increased release of PF4 during major surgery resulting in more immunogenic complexes 17 is one potential explanation for the enhanced immune response after major trauma. An alternative explanation might be that the surgical trauma by itself, or the inflammation associated with major surgery, modifies the immune system in a way to trigger B-cells specific for PF4-complexes. This would be consistent with the observation that HIT is less frequent in medical patients and in pregnant women as compared to surgical patients. 18 However, it is difficult to control for the effect of inflammation in a clinical study in trauma patients and to differentiate between the effect of inflammation and potential other confounders. This issue might be better addressed in one of the mouse models of the HIT immune response. 19, 20 The somewhat longer exposure to
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From heparin after major surgical procedures may also have contributed to the difference in immunization rates. However, both groups were tested for PF4/heparin antibodies at the same time (day 10.6 and day 11.0, respectively). As most immune responses to PF4/heparin start within the first week 21, 22 the immune response should have been detected by our study in both groups with a similar likelihood.
An interesting parallel to the present study is the enhanced risk for the induction of antibodies against FVIII in patients with hemophilia receiving FVIII concentrates during episodes of inflammation and surgery. 23, 24 This indicates the intriguing possibility that not only the immune response of HIT but also the immune responses to other biotherapeutics might be driven considerably by transient nondrug patient-related factors, e.g. induced by tissue trauma.
The study further corroborates that the immune response to PF4/heparin is less frequent in trauma patients receiving low-molecular-weight heparin as compared to unfractionated heparin. It was not powered to detect a statistically significant difference in clinical HIT between the two heparin groups. However, in the view of earlier studies, [7] [8] [9] [10] [11] it provides further evidence that using low-molecular-weight heparin instead of unfractionated heparin for thrombosis prophylaxis is most likely an efficient measure to reduce the risk for HIT in a general trauma patient population. As these previous studies utilized the LMWH enoxaparin, the fact that risk reduction was seen in our study with another LMWH (certoparin) is worth noting as possible evidence of a class effect.
Our study corroborates the previously noted gender imbalance in HIT Our study also indicates that in trauma patients the recommendation of guidelines 12, 25 and package inserts (Germany, France) to monitor platelet counts in all patients who receive heparin could be restricted to patients with major trauma and potentially limited to patients receiving unfractionated heparin. This would reduce a major burden of care during prolonged thrombosis prophylaxis in out-patients with minor trauma.
Interestingly, in this study unfractionated heparin and low-molecular-weight heparin showed the same efficacy for preventing DVTs. This is different to the study of Geerts et al (1996) 26 which found a significant risk reduction of all DVTs of 30% (95% CI 4-50%, p=0.014) by low-molecular-weight heparin compared to unfractionated heparin. However, these authors enrolled only patients with major trauma and compared a higher dose of low-molecular-weight heparin (enoxaparin 30 mg b.i.d.) with a lower dose of unfractionated heparin (5,000 IU b.i.d). We tested 3,000 anti-FXaU certoparin once per day and unfractionated heparin (5,000 IU t.i.d.).
In conclusion, our study has shown for the first time that the magnitude of trauma, and resulting need for major versus minor surgery, is a major risk factor influencing the immune response of HIT. It further extends the finding that lowmolecular-weight heparin may be safer than unfractionated heparin with regard to triggering HIT in patients receiving thrombosis prophylaxis after major trauma as it induces HIT-antibody seroconversion-and the corresponding risk of HIT-less frequently. Given the wide use of heparin, the anti-PF4/heparin immune response is a potential model to better understand important confounders of immune reactions towards biotherapeutics in humans.
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